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To provide an integrated view of endoplasmic
reticulum (ER) function in protein export, we
have described the interdependence of protein
folding energetics and the adaptable biology of
cellular protein folding and transport through
the exocytic pathway. A simplified treatment
of the protein homeostasis network and a for-
malism for how this network of competing
pathways interprets protein folding kinetics
and thermodynamics provides a framework for
understanding cellular protein trafficking. We il-
lustrate how folding and misfolding energetics,
in concert with the adjustable biological capac-
ities of the folding, degradation, and export
pathways, collectively dictate an adaptable
standard for protein export from the ER. A
model of folding for export (FoldEx) establishes
that no single feature dictates folding and trans-
port efficiency. Instead, a network view pro-
vides insight into the basis for cellular diversity,
disease origins, and protein homeostasis, and
predicts strategies for restoring protein homeo-
stasis in protein-misfolding diseases.
INTRODUCTION
One third of the eukaryotic proteome is folded by the en-
doplasmic reticulum (ER) for delivery to downstream com-
partments that form the diverse membrane architectures
defining the exocytic and endocytic pathways of eukary-
otic cells. An understanding of the principles regulating
protein folding and export from the ER versus degradation
is important, because defects in partitioning are the foun-
dation for many protein-misfolding diseases (Aridor, 2007;
Cohen and Kelly, 2003). Mutations in cargo proteins canClead to loss-of-function diseases because of the failure
of those proteins to be selected by the coatomer complex
II (COPII) export machinery directing ER export (Gurkan
et al., 2006), resulting in their removal by the ER-associ-
ated degradation (ERAD) pathway (Brodsky, 2007). Exam-
ples include the DF508 cystic fibrosis transmembrane
conductance regulator (CFTR) protein responsible for
cystic fibrosis (Guggino and Stanton, 2006), variants of
a1-antitrypsin (a1AT) leading to childhood emphysema
(Perlmutter, 2006), and N370S b-glucocerebrosidase
responsible for the majority of Gaucher disease cases
(Sawkar et al., 2006). Other mutations, such as the Z var-
iant of a1AT, can result in misfolded protein accumulating
in the ER, triggering an unfolded protein response and ap-
optosis, with apoptosis being the outcome when protein
homeostasis cannot be reestablished (Perlmutter, 2006).
In contrast, the gain-of-toxicity category of protein-mis-
folding diseases, including the amyloidoses, are believed
to result from aggregation-prone proteins being efficiently
exported from the ER, after which they misassemble into
pathogenic structures in the extracellular space (Cohen
and Kelly, 2003; Page et al., 2005; Sekijima et al., 2005).
The ER-assisted folding (ERAF) pathways (Sekijima
et al., 2005), which are essential for protein export, use
many chaperones and folding catalysts to direct the fold-
ing of both lumenal and cytosolic domains (Shimizu and
Hendershot, 2007). The folding of ER lumenal domains is
aided by abundant chaperones including BiP and the
Hsp90-related GRP94 components, as well as the cal-
nexin/calreticulin cycle facilitating N-linked glycoprotein
folding (Helenius and Aebi, 2004). Folding catalysts
include protein disulfide isomerases (PDI) and cis/trans
peptidyl-prolyl isomerases. In addition to assisting the
folding of soluble exported cargo proteins, these ER
lumenal chaperones and folding enzymes collaborate
with cytosolic chaperones to coordinate the folding of
transmembrane proteins having cytosolic domains. The
cytosolic chaperones include Hsc-Hsp40/70 and Hsp90
members (Bukau et al., 2006; Queitsch et al., 2002; Young
et al., 2004). Metabolites and other small molecules thatell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc. 809
bind to native proteins can also stabilize them in either the
ER or the cytosol, enabling export (Sawkar et al., 2006; Se-
kijima et al., 2005). The ERAF pathways that link protein
cargo to the COPII export machinery are in competition
with the ERAD machinery directing dislocation from the
ER, targeting the protein to the cytosolic proteasome for
degradation. The ERAD, ERAF, and COPII export path-
ways comprise a versatile and integrated biological net-
work that directs ER function, although a rigorous quanti-
tative assessment of the relative contributions of these
pathways in (patho)physiology remains to be established.
Although there is evidence that protein export efficiency
decreases as thermodynamic stability decreases (Kowalski
et al., 1998; Kumita et al., 2006; Sekijima et al., 2005), this
correlation is a special case requiring the folding kinetics
to be fast (Sekijima et al., 2005). We recently utilized trans-
thyretin (TTR) variants with a wide range of folding kinetics
and thermodynamics to correlate the level of protein cargo
export with folding energetics. Thermodynamic and kinetic
parameters were integrated to generate a folding stability
score (Sekijima et al., 2005), providing a means to appreci-
ate their relative contribution to protein export through the
secretory pathway.
To render the insight gained with TTR more useful and
even predictive, we present a quantitative model of ER
function in folding for export (referred to as FoldEx) herein.
FoldExcombinesprotein foldingenergeticsandasimplified
Michaelis-Menten treatment of the protein homeostasis
network comprising the ERAF, ERAD, and export path-
ways, rationalizing a large body of existing experimental
results and enabling predictions to be made where exper-
imental data are lacking. By treating pathways as discrete
entities analogous to enzymes, we can recapitulate
theessenceof the folding/export/degradationnetwork. The
energetics of the protein of interest is evaluated by the
components of the ERAF, ERAD, and export machineries
by binding to unfolded, misfolded, and folded protein
states to dictate export efficiency. Different cells have
distinct distributions and concentrations of ERAD, ERAF,
and export components and will therefore have different
export capacities and efficiencies (Sekijima et al., 2005).
For example, choroid plexus cells secrete the same rela-
tively unstable transthyretin variants that liver cells largely
degrade (Sekijima et al., 2005). FoldEx enables an integra-
tion of protein energetics with the concentration and distri-
bution of the ERAD, ERAF, and export pathway compo-
nents which together dictate cellular protein export
efficiency. FoldEx uses parameters defining the physical
chemistry of protein folding and the biology of folding path-
ways, thus providing a robust framework to rationalize the
operation of the exocytic pathway in the context of eukary-
otic cellular diversity.
RESULTS
Energetic Principles of ER Export
The populations of the unfolded (U), misfolded (M), and
folded (F) conformational ensembles or states are dictated810 Cell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc.by their energies, as depicted by an energy landscape
model wherein each point in the x-y plane represents
a unique conformation with an energy defined by the z
coordinate (Figure 1A) (Oliveberg and Wolynes, 2005).
The influence of a destabilizing mutation on protein export
is partly attributed to altered energies and populations
of specific conformational ensembles. The unfolded
wild-type (U) and mutant (U0) conformational ensembles
(Figures 1A and 1B, respectively) of a given hypothetical
protein are assumed to lack extensive specific interresi-
due contacts and therefore have nearly equal energies.
In contrast, the differences in energy between wild-type
(WT) and mutant folded ensembles (F and F0) are typically
larger, because specific interresidue contacts are locally
disrupted by the mutation. The misfolded state is defined
as a nonnative, conformationally heterogeneous ensem-
ble of states largely lacking native contacts, which cannot
efficiently revert to U and F. Thus, the influence of a muta-
tion on the M state is generally modest due to its confor-
mational heterogeneity. As illustrated in Figure 1B, muta-
tions generally destabilize the F ensemble, leading to
higher populations of U and M.
These population changes provide a mechanism for
regulating export from the ER. The increased populations
of U0 andM0 in themutant protein facilitate increased inter-
actions with components of the ERAD and ERAF path-
ways, increasing protein flow to degradation and recovery,
respectively. Furthermore, the decreased population of F0
reduces its interaction with the export machinery, thereby
decreasing protein export from the ER.
The heights of the energy barriers separating the U, M,
and F (U0, M0, and F0) ensembles determine the rates
at which these states interconvert. When equilibration
between these ensembles is slow relative to the export
rate because of high energy barriers, kinetics have a strong
influence on the steady-state populations of U, M, and F
and therefore on export efficiency along with the influence
of thermodynamics.
Experimental Foundation for Understanding
ER Export
The reasonable assumption that ER export is regulated
through bimolecular interactions between U, M, and F
and components of the export, ERAF, and ERAD machin-
eries allows us to evaluate the influence of folding kinetics
and thermodynamics on export efficiency. The assumption
that the F ensemble engages the export machinery can be
qualitatively tested by plotting the measured thermody-
namic stability versus the measured cellular export effi-
ciency for bovine pancreatic trypsin inhibitor (BPTI) from
yeast (Kowalski et al., 1998) and a monomeric construct
of transthyretin (M-TTR) from baby hamster kidney (BHK)
cells (Sekijima et al., 2005) (fast-folding proteins). The fold-
ing equilibrium constant (referred to as KU/F) determines
the concentration of protein in the F and U ensembles at
equilibrium. The folding free energy (DGU/F) and folding
equilibrium constant (KU/F) are related by the equation
DGU/F = –RT lnKU/F, indicating that the folding free
energy can be used to define a folding equilibriumconstant
for each exported protein (Fersht, 1999).
Figure 2 shows that export efficiency is close to 0 for
very unstable proteins, then increases as stability in-
creases until an upper limit is reached; that is, export effi-
ciency has a sigmoidal dependence on KU/F (when KU/F
is plotted on a log scale). Likewise, the dependence of the
population of the F ensemble on KU/F is similar, qualita-
tively supporting the hypothesis that export efficiency is
related to the population of the F ensemble. Furthermore,
the data in Figure 2 enable us to test another hypothesis:
that no matter how complicated the export pathway actu-
ally is (Gurkan et al., 2006), it can be treated as though it
were an enzyme. Like an enzyme, we propose that the ex-
port pathway recognizes a protein fold, its substrate, with
a given binding constant and then exports it with a given
kinetic constant. The hypothesis that the ERAF and
ERAD pathways can be similarly simplified, without losing
insight into the competing ERAD, ERAF, and export net-
works, can be directly tested.
Figure 1. Illustration of a Protein Folding Energy Landscape
Conformational coordinates (x and y axes) and energies (z axis) for
conformational ensembles associated with a wild-type (A) and a desta-
bilized mutant (B) protein. Depressions in the plot indicate ensembles
of conformations corresponding to the unfolded (U and U0), misfolded
(M and M0), and folded (F and F0) populations.CThe FoldEx Model of Protein Export from the ER
A model of folding for export (FoldEx), based on the inter-
play between protein kinetics and thermodynamics and
a Michaelis-Menten treatment of the adaptable biology
of the ERAD, ERAF, and export machineries (thinking of
each ‘‘pathway’’ as an ‘‘enzyme’’) is illustrated by Figure 3.
Exported proteins are cotranslationally inserted into the
ER through the Sec61 translocon, denoted with a T (path-
way 1). In the absence of chaperones, the unfolded con-
formational ensemble (U) would simply be released into
the ER when protein translocation is complete (pathway
2). However, the nascent, unfolded polypeptide is gener-
ally bound by a chaperone(s) from the ERAF pathway
(pathway 3) as it is being inserted into the ER (TUC1). These
chaperones typically have a low-affinity (ADP-bound)
state and a high-affinity (ATP-bound) state. The nascent
protein is initially bound by chaperones in the high-affinity
state, after which the chaperone-protein complex (C1U) is
released into the ER lumen (pathway 4). When the chaper-
one converts from the high-affinity to the low-affinity state
in response to ATP hydrolysis (C2U) (pathway 5), it liber-
ates the protein (pathway 6), affording it the opportunity
Figure 2. Dependence of Protein Export Efficiency on Protein
Folding Thermodynamics
A plot of export efficiency versus thermodynamic stability (KU/F) for
(A) bovine pancreatic trypsin inhibitor (BPTI) in yeast (Kowalski et al.,
1998) and (B) a monomeric construct of transthyretin (M-TTR) from
baby hamster kidney (BHK) cells (Sekijima et al., 2005). Data from
Kowalski et al. were converted from folding free energies (DGU/F)
to folding equilibrium constants (KU/F) via the equation
KU/F = e
DGU/F=RT, where R = 1.987 kcal mol1 K1 and T is tempera-
ture in Kelvin. The dotted lines are fits of the FoldEx model (Figure 3) to
the data.ell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc. 811
Figure 3. FoldEx Model of Protein Export
Protein homeostasis in the ER lumen (gray) is influenced by the interacting ERAF (green), ERAD (red), and ER export (blue) pathways. The rate
constants for each pathway are listed in the boxed inset, with the values used for them in parentheses (see also Table S1).to fold. The released chaperone will switch back to its
high-affinity state through ATP binding (not shown). If the
protein fails to fold, the unfolded conformational ensemble
can rebind to a chaperone and go through another ERAF
cycle (pathway 7) as defined by the green box. Alterna-
tively, it can reversibly adopt a properly folded ensemble
of conformations (F) (pathway 8), which can be bound by
the ‘‘export machinery’’ (E) and exported (pathways 9
and 10; blue box). If the protein fails to complete folding,
U can engage the ERAD pathway (11 and 12; red box);
that is, it can be recognized by the ‘‘retrotranslocation ma-
chinery’’ (R) and sent to the cytosol to be degraded by the
proteasome (Brodsky, 2007). Although it is generally be-
lieved that the U ensemble is only recognized by the
ERAD pathway after multiple unsuccessful attempts at
folding, the role of chaperones in recruiting substrates to
ERAD (Brodsky, 2007) and the cotranslocational degrada-
tion of certain ER cargo proteins (Oyadomari et al., 2006)
suggest that this is not the case. Moreover, the FoldEx
model suggests that the fact that U can be recognized
by ERAD does not necessarily result in a significant
amount of ERAD unless there is a folding energetic defect
(see below). Finally, the unfolded protein can misfold
(pathway 13), thus populating the M state. In the first iter-
ation of thismodel, we assume thatmisfolded proteins can
only return to U with the assistance of chaperones (path-812 Cell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc.way 14; green box) because misfolded states including
amorphous aggregates typically have high unfolding bar-
riers. Misfolded proteins can also be recognized by the
retrotranslocation machinery and be degraded by ERAD
(pathways 15 and 16; red box).
Using FoldEx to Gain Insight into the Link
between Export Efficiency and Energetics
To discern whether ER function in protein export is accu-
rately described using FoldEx, we examined the influence
ofmodel parameters on ERAF, ERAD, and export capacity
(Figure 3). These parameters can be systematically varied
to predict their role in export efficiency, whichwe define as
the ratio of the export rate to the synthesis rate at steady
state. To calculate the export efficiency, we assigned
rate constants that describe each bimolecular interaction
and folding reaction (Figure 3). In addition, various concen-
trations of the export machinery ([E]tot), retrotranslocation
machinery ([R]tot), and chaperones ([C]tot) were explored.
Each of the abovemachineries consists ofmany compo-
nents. For example, in export, the F ensemble is selected
through soluble or transmembrane adaptor complexes
that are recruited to ER exit sites and into COPII-coated
vesicles that bud and traffic the protein cargo to down-
stream compartments (Gurkan et al., 2006). In this hypoth-
esis, the export machinery can be thought of as the
enzyme, ensemble F as the substrate, and the export
machinery-folded protein complex (EF) as the enzyme-
substrate complex. Thus, kcat for the export machinery is
kEF/E (i.e., the turnover rate for the enzyme-substrate
complex), Vmax is kEF/E$[E]tot (i.e., the maximum rate of
product formation at a given enzyme concentration), and
KM is (kEF/E+F + kEF/E)/kE+F/EF (i.e., the concentration
of substrate at which product formation is 1⁄2 Vmax). As
a second example, there is a large body of evidence that
ERAD consists of many ER components that likely recog-
nize U and M and deliver these conformational ensembles
to the retrotranslocon for retrotranslocation and degrada-
tion (Brodsky, 2007). As with export, we have assumed
that the retrotranslocation machinery can be represented
as a single entity and retrotranslocation as a two-step pro-
cess. Again, this assumption allows us to use Michaelis-
Menten enzyme kinetics for ERAD, where kcat = kRX/R,
Vmax = kRX/R$[R]tot, andKM= (kRX/R+X + kRX/R)/kR+X/RX,
where X = U or M.
Rate constants used in the FoldExmodel were based on
experimental data when possible (see Figure 3). In the
absence of experimental data, estimates typical for the
processes involved were used. These parameters were
inserted into the rate equations, which were then solved
for the steady state to yield the synthesis and export rates
necessary to calculate the relative export efficiency under
the specified conditions. Although FoldEx includes basic
parameters that can be systematically varied to scrutinize
the model to determine their validity based on established
experimental data and to reveal new features of ER func-
tion for protein export, we recognize that it could be further
elaborated in many ways. The chaperoning cycle could
encompass the more elaborate calnexin-calreticulin cycle
for N-linked glycans (Helenius and Aebi, 2004); it could
include the influence of distinct chaperones and cocha-
perones (Gonzalez et al., 2002); more accurate models
of unimolecular protein misfolding and multimolecular ag-
gregation (brought about, for example, by chaperone con-
centrations falling below a critical level) could be used
(Rieger et al., 2006); the biological pathways could be rep-
resented as integrated systems with positive and negative
regulation (Robinson and Lauffenburger, 1996); and multi-
domain protein engagement of the export machinery
could be defined on the basis of the folding energetics
of the relevant domain. These additional features would
make the model more realistic, but they would also
make it more complex. A virtue of FoldEx is its simplicity,
especially if such a model can explain experimental data
andmake predictions where data are lacking. Importantly,
this simplicity allows the effects of changes in model
parameters to be clearly defined.
The first test of FoldEx was to discern whether integrat-
ing protein folding energetics and the biology of protein
homeostasis could recapitulate the experimental data in
Figure 2. The dotted lines generated using FoldEx demon-
strate that this model can reproduce the form of the
experimental cellular export data for BPTI (Kowalski
et al., 1998) andM-TTR (Sekijima et al., 2005). That the ex-Cport efficiencies of two different proteins in two different
cell types, one a lower eukaryote (yeast) and the other
a higher eukaryote (BHK cells), can be described using
the same model reflects the evolutionary conservation
of protein export regulation.
Export Efficiencies of Fast-Folding Proteins
Depend on Thermodynamics
We will first examine the influence of folding thermody-
namics in determining export efficiency using FoldEx.
This is best accomplished by modeling a monomeric
protein that folds much faster than it can be exported or
retrotranslocated and does not misfold (kU/M = 0). Chap-
erones would be unnecessary for such proteins, so they
are not considered here ([C]tot = 0), although chaperones
can bind unfolded proteins, thus preventing them from
folding and slowing the observed protein folding rate.
Nevertheless, modeling with FoldEx demonstrates that
neglecting chaperones in this case does not affect export
efficiency; see Supplemental Experimental Procedures.
The steady-state export efficiency versus the folding
equilibrium constant (KU/F) for fast-folding proteins is
plotted in Figure 4. The folding equilibrium constant KU/F
Figure 4. The Effect of Protein Folding Thermodynamics on
Export Efficiency and the MxT for a Fast-Folding Protein
(A) Plots of export efficiency versus thermodynamic stability (KU/F).
The activities of the export and retrotranslocation pathways are ex-
pressed in terms of the concentrations of these machineries ([E]tot,
[R]tot), respectively. The dotted line represents the minimal export
threshold (MxT), here set at export efficiency = 0.1.
(B) A plot of MxT as a function of [E]tot and [R]tot.ell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc. 813
is the ratio of the folding and unfolding rate constants (e.g.,
KU/F = kU/F/kF/U). The concentrations of export ([E]tot)
and retrotranslocation ([R]tot) machineries were both set
to 0.1 mM to balance their influence on export efficiency.
The black curve shows that the model gives the result re-
quired by experimental observations: the dependence of
export efficiency on thermodynamic stability is sigmoidal,
reaching a maximum of 1. It is therefore possible for fast-
folding proteins with substantially destabilizing mutations
to be exported with essentially the same efficiency as
more thermodynamically stableWT variants. For example,
if a WT protein had KU/F = 10
4, the black curve in Fig-
ure 4A shows that it would have an export efficiency of
1.0. If a mutation decreased KU/F to 10
2 (a factor of
100), the export efficiency would still be nearly 1.0. The ex-
port efficiency of the mutant protein, in a given cell type, is
dictated by its absolute stability, not by its stability relative
to theWT protein, all else being equal. This effect has been
observed experimentally in the export of M-TTR (Sekijima
et al., 2005), as shown in Figure 2A.
Export Efficiencies of Fast-Folding Proteins
Depend on the Relative Activities of the Export
and ERAD Pathways
The rate constants and concentrations used for the ex-
port and retrotranslocation machineries in the preceding
section were the same. Thus, Vmax and KM for export and
ERAD were the same (the export and ERAD pathways
had the same activities). But what happens when the
two pathways have different activities? The colored
curves in Figure 4A show the dependence of the export
efficiency on the folding equilibrium constant for a fast-
folding protein when export is more active than ERAD
(light blue and blue curves), or when ERAD is more active
than export (orange and red curves). Export efficiencies
increase as the activity of the export pathway increases
(the export efficiency curve shifts to the left when [E]tot >
[R]tot), and decrease as the activity of the ERAD pathway
increases (the export efficiency curve shifts to the right
when [R]tot > [E]tot). Thus, the model suggests that mod-
est inhibition of ERAD could remedy excessive ERAD
and loss of function that leads to numerous familial
loss-of-function misfolding diseases, including Gaucher
disease.
The dependence of export efficiency on folding ener-
getics, ERAF, ERAD, and export activities can be best
illustrated in terms of a minimal export threshold (MxT),
defined as that equilibrium constant affording a certain
export efficiency (here we choose 0.1). TheMxT increases
as [R]tot increases and decreases as [E]tot increases
(Figure 4B), showing that the dependence of export effi-
ciency on protein folding energetics can shift dramatically
as the relative activities of the export and ERAD pathways
are altered. It should be noted that similar effects could be
obtained by altering the kcat or KM of the export and retro-
translocation machineries, for instance by allosteric regu-
lation or by interaction with accessory proteins. Thus, the
MxT is strongly influenced by the biology of ERAF, ERAD,
and export pathways.814 Cell 131, 809–821, November 16, 2007 ª2007 Elsevier IncExport Efficiencies of Slow-Folding Proteins
Are Sensitive to Protein Folding Kinetics
In the previous two sections, we assumed that protein
folding was fast (equilibrium was reached before the
export or ERAD machinery could be engaged). This likely
will be true only for small monomeric proteins, because
folding rates tend to decrease as the size of the protein
increases (Li et al., 2004). Proteins that fold with moderate
or slow rates (relative to the rates of export and ERAD) are
susceptible to ERAD during the time that they are in the
unfolded conformational ensemble, which decreases their
export efficiency, even if they are thermodynamically sta-
ble once folded. This effect is illustrated by Figure 5A,
which consists of plots of export efficiency versus folding
equilibrium constant for proteins with progressively slower
folding reflected by increasing half-times for folding (t1/2,F).
The half-time is defined as the time required for a unimo-
lecular folding reaction to progress halfway to equilibrium:
t1/2,F = (ln 2)/(kU/F + kF/U). Again, the activities of the
export and ERAD machineries were set equal to each
other to focus on the effect of folding kinetics.
Figure 5A shows that, for a protein with a given folding
equilibrium constant, the export efficiency decreases as
t1/2,F increases. This effect is small at first, but becomes
substantial when the folding rate becomes comparable
to the rate at which the export and retrotranslocation
machinery operate. Given the rate constants in Figure 3
and [E]tot = [R]tot = 0.1 mM, this occurs when t1/2,F 
10 s. Thus, even very stable proteins may be degraded
to a considerable extent if they fold slowly, an important
issue for large, multidomain proteins such as CFTR and
other transmembrane proteins that can require up to
10min for synthesis and folding (Riordan, 2005). Figure 5A
shows that a very stable protein with a folding equilibrium
constant (KU/F) of 10
4 would have an export efficiency of
only 0.4 when its t1/2 of folding is 10 s. Figure 5B further
illustrates the effect of folding kinetics on the MxT; KU/F
is plotted on the horizontal axis and the t1/2,F of folding is
plotted on the vertical axis, whereas the curved black
line represents the MxT. The KU/F, t1/2,F combinations
that fall in the red region of the plot are below the MxT,
and those in the light blue region are above the MxT.
Figure 5B shows that the MxT is largely independent of
the folding rate when folding is much faster than ERAD
and export (a t1/2,F < 1 s for this case), and that the MxT
cannot be reached no matter how stable a protein is when
folding ismuch slower than ERADand export (a t1/2,F > 70 s
in this case), hence FoldEx predicts that pharmacologic
chaperones (native state stabilizing small molecules)
would be ineffective in this case, whereas a decrease in
ERAD activity could provide these proteins an opportunity
to fold. In contrast, the MxT is strongly dependent on both
stability and folding rate at intermediate folding rates (1 s <
t1/2,F < 70 s). This indicates that both substantially contrib-
ute to export efficiency at a given balance of ERAF, ERAD,
and export machineries and that proteins with intermedi-
ate folding rates that arise from mutation are more ‘‘cor-
rectable.’’.
Figure 5. The Influence of Protein Folding Kinetics on Export Efficiency in the Absence of Protein Misfolding
(A) A plot of the export efficiency versus stability for proteins with varying folding rates (t1/2,F). The dotted line represents the MxT.
(B) A plot of theMxT (black curve) as a function of protein folding kinetics and thermodynamics ([E]tot = [R]tot = 0.1 mM). The values of t1/2,F and KU/F on
this line give an export efficiency of 0.1. The regions of the plot shaded blue and light red contain values of KU/F and t1/2,F above and below the
minimal export efficiency, respectively.
(C) A plot of export efficiency versus stability for a protein with t1/2,F = 1 s at varying values of [E]tot and [R]tot. The dotted line represents the MxT.
(D) Plots of the MxT as a function of protein folding kinetics and thermodynamics at varying values of [E]tot and [R]tot.Slow-Folding and Fast-Folding Proteins Differ
in Their Responses to Export and
Retrotranslocation Activity Changes
Figure 4 demonstrates that the export efficiencies of fast-
folding proteins such as TTR depend on the relative activ-
ities of the export and ERAD pathways and that the effects
of the two pathways on export are symmetrical. This
means that increasing the concentrations of the export
or retrotranslocation machineries shifts the export effi-
ciency versus folding equilibrium constant curve in oppo-
site directions, but to equal degrees. This symmetry no
longer exists for slow-folding proteins such as CFTR.
Figure 5C consists of FoldEx plots of export efficiency
versus the folding equilibrium constant at several values
of [E]tot and [R]tot for a protein with a t1/2,F of 1 s. Here, in-
creasing [E]tot initially improves export substantially, but
this increase is attenuated as [E]tot continues to increase.
Increasing [R]tot has a strong negative effect on the export
efficiency; moderately high concentrations of [R]tot almost
eliminate export, even for very stable proteins (Figure 5C).This asymmetry is evident in theMxT representation of the
data (Figure 5D). As the [E]tot decreases relative to a fixed
[R]tot (Figure 5D, panels 1–3), the MxT will support export
of only increasingly stable and fast-folding proteins. The
MxT retreats to smaller and smaller portions of the upper
right-hand corners of the plots when [R]tot R [E]tot
(Figure 5D, panels 3–5), indicating that proteins must
fold faster and bemore stable to be exported with minimal
efficiency when [R]tot > [E]tot. Hence, increasing relevant
export activity and/or decreasing ERAD activity is pre-
dicted to restore export and function in cases where ex-
cessive ERAD leads to loss-of-function diseases.
The asymmetric effects of the export and ERAD activi-
ties on the export efficiency of slow-folding proteins is
caused by a change in the rate-limiting step in the export
pathway as [E]tot increases. The rate at which the export
machinery operates is proportional to [E]tot (as Vmax is pro-
portional to [E]tot). When folding is fast, it is unlikely that
[E]tot can ever become large enough for export to be faster
than folding. Thus, export is always the rate-limiting stepCell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc. 815
for fast-folding proteins. However, when folding is not fast,
export can become faster than folding when [E]tot (and
therefore the Vmax for export) is sufficiently large. Folding
then becomes the rate-limiting step in the export pathway,
and thus the effect of increasing [E]tot on the export effi-
ciency diminishes. ERAD is different from export in that
there are no steps between the unfolded conformational
ensemble and its recognition by the retrotranslocation
machinery. ERAD is always rate limited by the rate
at which the retrotranslocation machinery operates, and
increasing the concentration of the [R]tot consequently
has a strong effect on export efficiency for both fast-
and slow-folding proteins; thus, modest ERAD inhibition
could have a substantial impact in protein homeostasis
diseases.
Chaperones Improve Export Efficiency
for Proteins Prone to Misfolding
by Altering the MxT
Wehave assumed thatmisfolded proteins cannot revert to
the unfolded state without the assistance of the chaper-
ones found in the ERAF pathway. In the absence of the
ERAF pathway, the only option for a misfolded protein is
ERAD. Misfolding would therefore irremediably decrease
export efficiency. The ERAF pathway, however, can com-
pete with ERAD to recover misfolded proteins. Chaper-
ones can interact with misfolded/misassembled proteins
and convert them to unfolded proteins (Bukau et al.,
2006; Young et al., 2004), giving them another chance to
fold and be exported (Figure 3). This increases the export
efficiency of misfolding-prone proteins (Gurkan et al.,
2006; Wang et al., 2006).
The effect of protein misfolding on export efficiency is
illustrated by Figure 6A, which consists of plots of export
efficiency versus folding equilibrium constant (stability)
for proteins with a series of increasing misfolding rates.
Themisfolding rate is represented by the half-time for mis-
folding (t1/2,M = (ln 2)/kU/M). Here we find that the export
efficiency decreases as proteinmisfolding becomes faster
(i.e., as t1/2,M decreases), even for very stable proteins.
Thus, when protein misfolding is significant, the MxT
depends not only on the thermodynamics and kinetics of
folding but also on the kinetics of misfolding. We can
therefore plot the MxT for misfolding-prone proteins in
the absence of chaperone ([C]tot = 0) as a surface in Fig-
ure 6B. This plot shows that the MxT constricts for a given
value of stability (x axis) as the misfolding rate (z axis) in-
creases and the folding rate (y axis) decreases. FoldEx
demonstrates that proteins that misfold quickly are un-
likely to be exported efficiently, unless they fold even
faster and are very stable once folded.
Chaperones in the ERAF pathway afford misfolded pro-
teins another opportunity to fold. We refer to this adapt-
able environment as the modular ‘‘chaperome’’ (Wang
et al., 2006), where the word ‘‘modular’’ reflects the
capacity of various chaperone activities to be tunable
through their steady-state concentrations and through
the influence of cochaperones, other regulatory mole-
cules, and posttranslational modifications. Thus, increas-816 Cell 131, 809–821, November 16, 2007 ª2007 Elsevier Incing the activity of the chaperome (in this case [C]tot)
increases the activity of the ERAF pathway, making the
chaperome environment more pro-folding and increasing
export efficiency (Figure 6C; t1/2,F = t1/2,M = 1 s). At the
highest chaperome concentration, if biologically feasible,
FoldEx predicts that misfolding could be eliminated.
Figure 6D shows that the MxT encloses a larger volume
in the plot as [C]tot increases (from 0.1 mM in panel 1 to
10 mM in panel 3). It also becomes less sensitive to the
misfolding rate: at [C]tot = 10 mM, the MxT is independent
of the misfolding half-time, until t1/2,M < 1 s. The effect of
ERAF on protein export in the model is consistent with
many reports that chaperone overexpression increases
the export of proteins from cells (Borth et al., 2005; Xu
et al., 2005). Thus, the modular chaperome pool plays
a central role in adjusting the MxT to augment export effi-
ciency for both WT and misfolding-prone proteins. FoldEx
suggests that protein homeostasis modifiers that both
enhance ERAF and inhibit ERAD could restore folding
and export to proteins with substantially compromised
energetics.
DISCUSSION
We utilize a Michaelis-Menten treatment of the protein
homeostasis pathways (ERAD, ERAF, export) to model
endoplasmic reticulum function in protein export, an ap-
proach that integrates protein energetics into the deci-
sions made by the biological components of the ER.
This simplified model captures many features of the ER
that have not been comprehensively described previ-
ously, one being that the adjustable biological capacities
of the folding, degradation, and export pathways dictate,
in concert with folding energetics, an adaptable standard
for protein export. FoldEx also makes numerous unantic-
ipated testable predictions regarding the biology of the ER
that have a fundamental impact on our understanding of
protein homeostasis and cellular diversity in health and
disease.
An Adaptable Standard for Protein Export
There is a consensus that mutated proteins are degraded
by ERAD if they are less stable thanWT, or exported if they
are equally or more stable than WT (Helenius and Aebi,
2004). The FoldEx model moves beyond this ‘‘quality con-
trol’’ (QC) concept, revealing that export efficiency is influ-
enced by folding and misfolding energetics, as well as by
the adjustable biological activities of the ERAF, ERAD, and
export pathways specific to each cell type. Thus, there is
no one QC standard for export. A variable standard is
a key feature of ER function that is more appropriately
thought of as protein homeostasis control than QC, given
the need to adapt protein cargo folding to normal cellular
function. Thus, FoldEx explains why different cell types
handle the same WT or mutant protein differently, depen-
dent on their unique biology and the expressed proteome
in the cell of interest..
Figure 6. The Effect of Misfolding Rate and ERAF on Protein Export Efficiencies
The values of [E]tot and [R]tot were set to 0.1 mM to generate the plots in all panels.
(A) Plots of the export efficiency versus stability for proteins with amoderate folding rate (t1/2,F = 1 s) and variable misfolding rates (t1/2,M) when ERAF is
unavailable ([C]tot = 0).
(B) Plot of MxT as a function of protein stability (KU/F), folding kinetics (t1/2,F), and misfolding kinetics (t1/2,M). The values of KU/F, t1/2,F, and t1/2,M on
the blue surface give an export efficiency of 0.1, the MxT.
(C) Plots of the export efficiency versus stability for a protein that misfolds with t1/2,F = t1/2,M = 1 s at varying levels of ERAF activity (expressed in terms
of the chaperone concentration, [C]tot, 0–10 mM).
(D) As in (B), except that [C]tot has been set to 0.1, 1, and 10 mM in panels 1, 2, and 3, respectively.Predictions from the FoldEx Model
for Normal Cellular Physiology
FoldEx rationalizes the observation that with some pro-
teins, thermodynamic stability correlates with export effi-
ciency (Kowalski et al., 1998), whereas in other cases,
both kinetics and thermodynamics strongly influence the
concentration of the folded state that can engage the ex-
port machinery (Sekijima et al., 2005). The model predictsthat the dependence of export efficiency on energetics
will be cell type specific. Moreover, two populations of
the same cell type or the same cell in different environ-
ments could have very different export efficiencies, de-
pendent on chaperone levels that could be upregulated
by the unfolded protein response (Ron and Walter,
2007) in only one population or biological state. FoldEx ra-
tionalizeswhy large slow-foldingmembrane proteins haveCell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc. 817
poor ER export efficiencies: because they fold slowly,
high concentrations of the U and M states can build up
that engage the ERAD pathway, such as is observed in
cystic fibrosis (Loo and Clarke, 2007). This also provides
a framework to understand why large multimembrane-
spanning proteins are unstable in suboptimal folding
environments such as heterologous expression systems.
FoldExmakes a number of predictions for protein homeo-
stasis control that could be tested by proteomic and tran-
scriptional analysis of highly specialized secretory cells.
For example, we would expect that hepatocytes or highly
specialized plasma B cells would have elevated ERAF/
export components to maximize protein export, as is ob-
served (Shimizu and Hendershot, 2007).
The FoldEx model emphasizes that a subset of proteins
will be in competition for the basic ERAD, ERAF, and
export machineries, and hence the export efficiency of
a particular cargo protein will depend on the proteome be-
ing expressed at that time and the activity of the ERAD,
ERAF, and export pathways. For example, FoldEx would
predict that if two proteins of dissimilar stability were
coexpressed, the less stable protein would outcompete
the more stable protein for the ERAD machinery, resulting
in higher export efficiency for the more stable protein. This
could explain why coexpressing bovine pancreatic trypsin
inhibitor (BPTI) and scFv D1.3 in yeast results in increased
export of BPTI and, notably, decreased export of scFv
D1.3 (Rakestraw and Wittrup, 2006). Moreover, a pro-
teomewith numerous destabilizing polymorphisms will re-
quiremorebiological folding assistance and render a given
destabilized protein more prone to ERAD than would
a more stable proteome. Because of competition for
both the ERAF and ERAD machinery, proteins with a pro-
pensity to aggregate (e.g., some variants of a1-antitrypsin;
Perlmutter, 2006) are more likely to do so in the presence
of a soluble misfolded protein cargo pool. This has been
observed in the cytosol for Huntington Poly Q aggregation
in the presence ofmisfolding-prone temperature-sensitive
mutant proteins that titrate cytosolic chaperones (Gidale-
vitz et al., 2006). Finally, the FoldEx model suggests that
many other factors including the ER redox state and ER
Ca2+ homeostasis will have a high impact on protein
homeostasis control given the requirement for PDI-like
activities and numerous Ca2+ binding chaperones, re-
spectively.
Predictions from the FoldEx Model
for Disease Intervention
Protein-misfolding diseases involving the secreted pro-
teome can be caused by ER export being either too per-
missive, resulting in export of aggregation-prone proteins
leading to proteotoxicity, or too restrictive, resulting in
loss-of-function disorders due to overzealous degradation
of proteins that have sufficient function to support physiol-
ogy. The FoldExmodel demonstrates that what is a benign
mutation in one cell type may be a disease-causing muta-
tion in another, reflecting physiologic differences, as ob-
served in Gaucher patients, wherein only a subset of the818 Cell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc.genetically identical monocyte/macrophage population
exhibits glucocerebrosidase enzyme deficiency sufficient
to cause glucosylceramide lysosomal storage. A similar sit-
uation is observed in cystic fibrosis patients, where identi-
cal siblings with the common DF508 mutation in CFTR
have different clinical courses. These and related observa-
tions demonstrate that there is a very fine line between
physiology and pathology, as predicted by FoldEx. Defin-
ing these differences is likely to yield critical insight into
disease.
The FoldEx model enables the balance between ERAD,
ERAF, misfolding kinetics, and export activities to be
varied to test therapeutic concepts for protein-misfolding
disease intervention. FoldEx predicts that no single strat-
egy can succeed for all loss-of-function or all gain-of-
toxicity protein-misfolding diseases, as is now evident be-
cause some mutations create kinetic challenges whereas
others largely influence thermodynamic stability. FoldEx
makes the important prediction that a chemical or biolog-
ical approach that simultaneously enhances ERAF and
partially inhibits ERAD should be a highly effective thera-
peutic strategy for loss-of-function diseases, especially
for the problematic mutations that lead to slow folding
and/or rapid misfolding such as the DF508 CFTR and
L444P glucocerebrosidase mutations associated with
cystic fibrosis and neuropathic Gaucher disease, respec-
tively. Moreover, our model suggests that enhancing fold-
ing capacity utilizing a pharmacologic chaperone (Aridor,
2007) should exhibit synergy with the aforementioned
approach, in which protein homeostasis is modulated,
because ERAF activators hasten folding and inhibit
misfolding by operating on conformational ensembles
preceding the folded state, whereas pharmacologic chap-
erones stabilize the folded state. Although we have em-
phasized the role of mutations in misfolding diseases,
type II diabetes is caused by excessive demand for the
production of WT insulin that cannot be met. FoldEx pre-
dicts that using a chemical or biological approach to bal-
ance the ERAF and export pathways selective for insulin
and amylin export would be an ideal strategy to ameliorate
pancreatic b cell death in type II diabetes (Ozcan et al.,
2006).
Additional FoldEx predictions for therapeutic strategies
can be visualized graphically (Figure 7) using the minimal
export threshold concept. The middle panel depicts two
mutations that fall outside the exportable pool defined
by the MxT, depicted by the transparent blue surface;
onemutation (m1) is outside theMxT because it is thermo-
dynamically destabilized and the second mutation (m2) is
outside the MxT because it has a fast misfolding rate. The
WT protein is inside the MxT, depicted by encasement
within the transparent blue surface. FoldEx demonstrates
that m1 can be brought inside the MxT by pharmacologic
chaperone-induced stabilization (Figure 7, top panel). In
contrast, the misfolding rate of m2 is too fast for
pharmacologic chaperone binding to bring it inside the
MxT. However, increasing the activity of the ERAF
machinery expands the MxT to the point that it places
Figure 7. Increasing ERAF and Pharmacologic Chaperoning
Have Distinct Influences on Different Loss-of-Function Dis-
ease Mutations
Center panel: three hypothetical proteins placed relative to the MxT
(represented by the transparent surface) according to their stability,
folding rate, and misfolding rate. The wild-type (WT) protein is repre-
sented by a blue point, and the two mutants (m1 and m2) are repre-
sented by red points. The first mutant (m1) is destabilized relative to
the wt, whereas the second (m2) misfolds much faster than wt. Top
panel: pharmacologic chaperoning can bring m1 but not m2 within
theMxT, enabling enhanced secretion of m1. Bottom panel: increasing
protein homeostasis capacity by increasing ERAF activity expands
the volume of the MxT, bringing m2 but not m1 within it, enabling
enhanced secretion of m2.Cm2 within the MxT, restoring function (Figure 7, lower
panel). The other mutant, m1, cannot be rescued in this
way because it does not populate the misfolded state
enough for ERAF-mediated recovery to substantially in-
crease its export efficiency. The validity of this strategy
was recently demonstrated: decreasing the levels of the
Hsp90 cochaperone Aha1 increased the level of CFTR
function on the surface of a patient-derived cell line
(Wang et al., 2006). FoldEx predicts that an even larger in-
crease in CFTR activity would be observed by also par-
tially inhibiting ERAD.
Alternatively, gain-of-toxic function diseases (e.g.,
systemic amyloidoses) resulting from the export of desta-
bilized proteins can be ameliorated by lowering the con-
centration of the exported protein. FoldEx predicts that
this could be achieved by enhancing ERAD of misfold-
ing-prone proteins. For example, overexpressing ERAD
components such as Derlin-2 or -3 increases degradation
of misfolding-prone glycoproteins (Oda et al., 2006). Sim-
ilarly, overexpressing EDEM in mammalian cells increases
degradation of a1-antitrypsin (Hosokawa et al., 2001; Oda
et al., 2003). These results demonstrate that the ERAD
machinery is a potential target for the treatment of amyloid
diseases.
Conclusion
A simplified Michaelis-Menten treatment of the protein
homeostasis network and a formal analysis of how the
network of competing pathways evaluates protein folding
kinetics and thermodynamics provide a framework for un-
derstanding the exocytic pathway for protein homeostasis
control. FoldEx shows how this understanding moves be-
yond the concept of quality control by rationalizing an
adaptable standard for protein export. FoldEx also makes
predictions about protein folding and trafficking that can
be tested experimentally, providing a rigorous framework
to develop new therapeutic strategies for loss- and gain-
of-function misfolding diseases.
EXPERIMENTAL PROCEDURES
Calculation of Steady-State Export Efficiencies
The steady-state export efficiency is the steady-state rate of protein
export divided by the steady-state rate of protein synthesis. The former
quantity is equal to the steady-state rate at which the export machinery
turns over, or kEF/E [EF]ss (the subscript ss refers to steady state).
Similarly, the latter quantity is equal to the steady-state rate at which
protein is released from the ribosome in both chaperone-bound and
-unbound forms, or kTU/T+U[TU]ss + kTUC1/T+C1U[TUC1]ss. To deter-
mine the steady-state concentrations of the species of interest, the
rate and mass balance equations of the FoldEx model must be solved
at steady state. The rate equations are
d½U
dt
= kTU/U½TU+ kC2U/C1+U½C2U+ kF/U½F+ kRU/R+U½RU




= kU/F½U+ kEF/E+F½EF  ðkF/U + kE+F/EF½EÞ½F (2)ell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc. 819
d½M
dt




= kTU/T+U½TU+ kTUC1/T+C1U½TUC1  kT/TU½T (4)
d½TU
dt
= kT/TU½T  ðkTU/T+U + kTU+C1/TUC1½C1Þ½TU (5)
d½TUC1
dt
= kTU+C1/TUC1½TU½C1  kTUC1/T+C1U½TUC1 (6)
d½C1
dt
= kC2U/C1+U½C2U  ðkTU+C1/TUC1½TU+ kC1+U/C1U½U
+ kC1+M/C1U ½MÞ½C1 (7)
d½C1U
dt




= kC1U/C2U½C1U  kC2U/C1+U½C2U (9)
d½E
dt
= ðkEF/E+F + kEF/EÞ½EF  kE+F/EF½E½F (10)
d½EF
dt
= kE+F/EF½E½F  ðkEF/E+F + kEF/EÞ½EF (11)
d½R
dt





= kR+U/RU½R½U  ðkRU/R+U + kRU/RÞ½RU (13)
d½RM
dt
= kR+M/RM½R½M  ðkRM/R+M + kRM/RÞ½RM: (14)
Four mass balance equations can be written for this system, one for
each of the classes of species that has a constant total concentration:
the translocon (including T, TU, and TUC1), the chaperone (including
C1, TUC1, C1U, and C2U), the export machinery (including E and EF),
and the retrotranslocation machinery (including R, RU, and RM):
½Ttot = ½T+ ½TU+ ½TUC1 (15)
½Ctot = ½C1+ ½C1U+ ½C2U+ ½TUC1 (16)
½Etot = ½E+ ½EF (17)
½Rtot = ½R+ ½RU+ ½RM: (18)
The right-hand sides of Equations 1–14 equal 0 at steady state,
allowing Equations 1–14 to be used to obtain expressions for [U]ss,
[F]ss, [M]ss, [TU]ss, [TUC1]ss, [C1U]ss, [C2U]ss, [EF]ss, [RU]ss, and
[RM]ss in terms of [T]ss, [C1]ss, [E]ss, and [R]ss. These expressions can
be inserted into Equations 15–18 to yield a set of four polynomial equa-
tions in [T]ss, [C1]ss, [E]ss, and [R]ss; for example, Equation 15 becomes









The equations for [C]tot, [E]tot, and [R]tot are muchmore cumbersome
than Equation 19 and are not shown here. Supplemental Data include
a file for the programMathematica 5.2 (Wolfram Research) that can be820 Cell 131, 809–821, November 16, 2007 ª2007 Elsevier Inc.used to obtain the remaining three polynomial equations. Given values
for [T]tot, [C]tot, [E]tot, and [R]tot and the rate constants, the four polyno-
mials can be solved for the values of [T]ss, [C1]ss, [E]ss, and [R]ss. These
four quantities can be inserted into the equations for the steady-state
concentrations of the other species to completely characterize the
steady state. The export efficiency can then be calculated using
the values of kEF/E, [EF]ss, kTU/T+U, kTUC1/T+C1U, [TU]ss, and
[TUC1]ss. Export efficiencies as functions of a given parameter were
made by varying the relevant parameter and solving the polynomial
equations for each value of the parameter (see Supplemental Data
for more information).
Steady-state solutions to the rate equations for FoldEx were calcu-
lated using Mathematica 5.2.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
one table, and one figure and can be found with this article online at
http://www.cell.com/cgi/content/full/131/4/809/DC1/.
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